Novo Nordisk India has partnered with Emcure Pharma to commercialise weight loss drug Poviztra in India, which will serve as a second brand of Wegovy. Emcure Pharma is the first Indian company to receive exclusive rights to distribute and commercialise Poviztra, a semaglutide injection of 2.4 mg for weight loss.
This partnership is part of Novo Nordisk’s initiative to make its innovative semaglutide molecule more accessible to the large population living with obesity in India. The goal is to reach more individuals through pharmacies and in areas not currently served by Novo Nordisk India. Wegovy (semaglutide injection 2.4 mg) was launched in India in June 2025.
Satish Mehta, CEO and MD of Emcure Pharma, expressed confidence in the potential of semaglutide in the Indian market. “With our strong understanding of the country’s diverse geographical landscape and established marketing capabilities, we are confident about making this molecule available to patients who need it the most.”
Currently, India has nearly 254 million people living with generalised obesity and another 351 million with abdominal obesity. Obesity is associated with over 230 health complications, including cardiovascular disease, fatty liver, knee osteoarthritis, polycystic ovary syndrome, kidney disease, and Alzheimer’s disease.
Jay Thyagarajan, senior vice-president for the APAC region at Novo Nordisk, highlighted the urgency of addressing the obesity crisis by launching Wegovy in India a few months prior. He noted that teaming up with Emcure Pharma will help broaden access.
This collaboration combines Novo Nordisk’s innovation in GLP-1 therapies with Emcure’s marketing and distribution strengths to improve access to obesity treatment for individuals living with overweight and obesity in India.